Table 2.
Methodology and outcome information of the included studies about ctDNA status.
| Study IDRef | Source of ctDNA | ctDNA detection method | Outcome | NOS score |
|---|---|---|---|---|
| An, 201922 | Blood | NGS | RFS/recurrence | 6 |
| Cai 201923 | Blood | NGS | Lead time | 5 |
| Wang, 202024 | Blood | ddPCR | RFS/OS/recurrence | 7 |
| Ge, 202125 | Blood | ddPCR and NGS | OS | 5 |
| Ye, 202218 | Blood | NGS | RFS/OS/recurrence | 7 |
| Zhu, 202226 | Blood | NGS | RFS/recurrence | 8 |
| Xia, 202227 | Blood | NGS | RFS | 5 |
| Lee, 202228 | Blood | NGS | OS | 7 |
| Xu, 202329 | Blood | NGS | RFS/recurrence | 6 |
| Campani, 202415 | Blood | ddPCR and NGS | RFS/OS | 9 |
| Huang, 202430 | Blood | NGS | RFS/recurrence | 9 |
| Hong, 202431 | Blood | NGS | Recurrence | 5 |
| Sogbe, 202417 | Blood | ULP-WGS | OS/PFS | 7 |
| Abdelrahim, 202232 | - | NGS | Recurrence/lead time | - |
| Jiang, 202233 | Blood | - | Recurrence/RFS | - |
| Pan, 202234 | Blood | NGS | RFS | - |
| Marron, 202335 | Blood | NGS | RFS/Lead time | - |
| Abdelrahim, 202436 | Blood | NGS | RFS | - |
| Guo, 202437 | Blood | NGS | Lead time | - |
Abbreviations: -, not reported; ctDNA, circulating tumor DNA; ddPCR, droplet digital Polymerase Chain Reaction; NGS, next-generation sequencing; NOS, Newcastle-Ottawa Scale; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival.